Jeffrey A. Barnes, Ph.D.
Affiliations: | 2004 | University of Illinois, Urbana-Champaign, Urbana-Champaign, IL |
Google:
"Jeffrey Barnes"Mean distance: 17.58 (cluster 32)
Parents
Sign in to add mentor| Martha Ulbrick Gillette | grad student | 2004 | UIUC | |
| (Conservation of Timeless in the mammalian circadian clock.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Mehta-Shah N, Horwitz SM, Ansell S, et al. (2020) NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020. Journal of the National Comprehensive Cancer Network : Jnccn. 18: 522-536 |
| Abramson JS, Irwin KE, Frigault MJ, et al. (2019) Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma. Cancer |
| Abramson JS, Arnason JE, LaCasce AS, et al. (2019) Brentuximab Vedotin, Doxorubicin, Vinblastine and Dacarbazine for Non-bulky Limited Stage Classical Hodgkin Lymphoma. Blood |
| Karschnia P, Jordan JT, Forst DA, et al. (2019) Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T-cells. Blood |
| Barnes JA, Redd R, Fisher DC, et al. (2018) Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study. Hematological Oncology |
| Chen ST, Barnes J, Duncan L. (2018) Primary cutaneous B-cell lymphomas- clinical and histopathologic features, differential diagnosis, and treatment. Seminars in Cutaneous Medicine and Surgery. 37: 49-55 |
| Horwitz SM, Ansell SM, Ai WZ, et al. (2018) NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018. Journal of the National Comprehensive Cancer Network : Jnccn. 16: 123-135 |
| Abramson JS, Redd RA, Barnes JA, et al. (2018) A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma Blood. 132: 1654-1654 |
| Bannerji R, Arnason JE, Advani R, et al. (2018) Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes Blood. 132: 1690-1690 |
| Bannerji R, Advani RH, Brown JR, et al. (2017) Safety and Preliminary Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-NHL Previously Treated with CD20-Directed Antibody Therapy Blood. 130: 1550-1550 |